SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical
company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced
that Tassos Gianakakos, chief executive officer, is scheduled to present at the Cowen and Company 37th Annual
Health Care Conference on Monday, March 6, at 1:20 p.m. ET. The conference is being held March 6-8, 2017, at the Marriott Copley
Place in Boston.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors &
Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the
treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical
defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic
programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM,
and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule
designed to reduce excessive cardiac muscle contractility leading to HCM and has been evaluated in three Phase 1 clinical trials.
MyoKardia is currently studying MYK-461 in the Phase 2 PIONEER-HCM trial in symptomatic, obstructive HCM (oHCM), a subset of HCM
for which the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation. MYK-491, the second clinical candidate
generated by MyoKardia’s product engine, is designed to increase the overall force of the heart’s contraction in DCM patients by
increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers; topline data
is expected in the third quarter of 2017. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry,
or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart
disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000
individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s mission is to change the
world for patients with serious cardiovascular disease through bold and innovative science. For more information, please visit
www.myokardia.com.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com
